<DOC>
	<DOCNO>NCT00809354</DOCNO>
	<brief_summary>The purpose study investigate long-term analgesic efficacy safety tanezumab patient osteoarthritis ( OA ) knee hip currently experience partial benefit , tolerate , non-steroidal anti-inflammatory drug ( NSAID ) therapy .</brief_summary>
	<brief_title>Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs ( NSAIDs ) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip</brief_title>
	<detailed_description>This study terminate 28 October 2010 follow US FDA clinical hold tanezumab osteoarthritis clinical study halt dose enrollment patient 23 June 2010 potential safety issue .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Anti-Inflammatory Agents , Non-Steroidal</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>Osteoarthritis knee hip accord ACR criterion KellgrenLawrence xray grade equal , great , 2 . Patients must experience benefit current stable dose regimen oral NSAID therapy either naproxen 5001000 mg/day celecoxib 200 mg/day ( either 100 mg BID 200 mg QD ) tolerate NSAID regimen . Pain level function level require protocol Screening Baseline . Willing discontinue nonstudy pain medication osteoarthritis except rescue medication ( acetaminophen ) use prohibit pain medication throughout duration study except permit per protocol . Willing able comply lifestyle guideline , schedule visit , treatment plan , laboratory test study procedure . Pregnant woman . BMI great 39 . Fibromyalgia , regional pain cause lumbar cervical compression radiculopathy moderate sever pain may confound assessment selfevaluation pain associate OA . Signs symptom clinically significant cardiac disease 6 month prior screen . Diagnosis TIA within 6 month prior screen diagnosis stroke residual deficit would preclude completion require study activity . History , diagnosis , sign symptom clinically significant neurological and/or psychiatric disease/disorder . At Screening : uncontrolled hypertension , hemoglobin A1c great equal 10 % , ALT AST great equal 3X upper limit normal , creatinine exceed 1.7 mg/dL ( men ) 1.5 mg/dL ( woman ) . Patients warfarin coumadin anticoagulant therapy and/or lithium therapy within 30 day prior screen . Known hypersensitivity NSAIDs cyclooxygenase inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>monoclonal antibody</keyword>
	<keyword>nerve growth factor ( NGF )</keyword>
	<keyword>anti-NGF</keyword>
	<keyword>tanezumab</keyword>
	<keyword>PF-04383119</keyword>
	<keyword>RN624</keyword>
	<keyword>osteoarthritis ( OA )</keyword>
</DOC>